Evidence map›Paper›PMID 38994622›Full record

ArticleRecent patents on anti-cancer drug discovery2025

Epigallocatechin Gallate Derivative Y

Chuan Huang, Si-Hong Wang, Tao-Tao Liu, Mei-Yi Wu, Kai-Ning Cai, Zhan-Hong Xie, Rui-Qiang Zhao, Yan Wen

Abstract read
PubMed Publisher
In one paragraph

Article in Recent patents on anti-cancer drug discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chuan HuangDepartment of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China.
Si-Hong WangDepartment of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China.
Tao-Tao LiuDepartment of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China.
Mei-Yi WuDepartment of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China.
Kai-Ning CaiDepartment of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China.
Zhan-Hong XieDepartment of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China.
Rui-Qiang ZhaoDepartment of Biochemistry and Molecular Biology, School of Preclinical Medicine, Guangxi Medical University, Nanning, 530021, China.
Yan WenDepartment of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China.

Funding

Education Department of Guangxi Zhuang Autonomous Region GXSWFZ202305Research Project of Western Medicine of Guangxi Health Commission Z-A20230585
6 · The paper itself

Abstract

backgroundThe emergence of drug resistance to oxaliplatin (OXA) is one of the critical obstacles in the therapy of advanced Hepatocellular Carcinoma (HCC). As an ethyl derivative of the natural compound epigallocatechin gallate (epigallocatechin-3-gallate, EGCG), Y

methodsMTT was used to determine the reversal effect of Y

resultsWe found that Y

conclusionY

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularCatechinDrug Resistance, NeoplasmLiver NeoplasmsOxaliplatinCell Line, TumorCell MovementEpithelial-Mesenchymal TransitionHumansHypoxia-Inducible Factor 1, alpha SubunitMicroRNAsNuclear ProteinsTwist-Related Protein 1Antineoplastic AgentsCatechinepigallocatechin gallateHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitMicroRNAsMIRN338 microRNA, humanNuclear ProteinsOxaliplatinTWIST1 protein, humanTwist-Related Protein 1EMTepigallocatechin-3-gallate (EGCG)miR-338-3p.oxaliplatin-resistanceresistance reversal agentY6

Identifiers

PMID38994622

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.